Navigation Links
Analysis Confirms Avandia May Harm the Heart
Date:3/17/2011

THURSDAY, March 17 (HealthDay News) -- A new analysis confirms that those who take the diabetes drug Avandia are more likely to develop heart problems and die than those who take a similar type of diabetes medication.

"The effect on public health may be considerable," the analysis authors wrote.

Avandia (rosiglitazone) helps control blood sugar levels in the body, and is prescribed for patients with type 2 diabetes. Studies in recent years have differed about whether it boosts the risk of heart disease and death.

In response to growing concerns over the drug's cardiovascular effects, U.S. health officials in September restricted the use of Avandia to patients with type 2 diabetes who cannot control their disease on other medications.

In the new analysis, researchers looked at the results of 16 studies that involved 810,000 users of Avandia or Actos (pioglitazone), a similar diabetes medication. The findings appear online March 17 in the BMJ.

The researchers found a "modest but statistically significant increase" in the odds of certain heart conditions in those who took Avandia. The risk of heart attack rose by 16 percent and increased 23 percent for congestive heart failure. Overall, mortality rates rose 14 percent.

Avandia is a common drug, with about 3.8 million prescriptions a year in the United States.

The analysis authors cautioned that Actos carries its own risks. Like Avandia, it's been linked to a doubling of risk of fracture in women. And researchers worry that it may slightly boost the risk of bladder cancer.

"Patients should review this study with their physician to gain a better understanding of how their personal circumstances may or may not be reflected in the study, and talk to their physicians about the risks versus the benefit of taking the drug," said Dr. Debra Wertz, outcomes research manager for HealthCore Inc., the research subsidiary of the insurance company WellPoint.

Wertz co-authored a 2010 study that found no significant differences in risk of heart attack, heart failure or death in patients who took the two drugs.

"One thing to consider is that the HealthCore study evaluated a population that is commercially insured and potentially younger [most were under 65] and healthier" than the studies analyzed in the meta-analysis, Wertz noted.

More information

For more about diabetes, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Debra Wertz, Pharm.D., outcomes research manager, HealthCore Inc., Wilmington, Del.; March 17, 2011, BMJ


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kaiser Analysis Finds Record Medicaid Enrollment Growth in 2009
2. New approach to immune cell analysis seen as first step to better distinguish health and disease
3. National Center for Policy Analysis and Salem Radio Network Deliver One Million Emails to Congress to Stop ObamaCare
4. Pregnancy for breast cancer survivors: Meta-analysis reveals it is safe and could improve survival
5. Improved device provides more rapid, comprehensive analysis of circulating tumor cells
6. Know What Works with Semantic Design's Test Coverage Analysis Tool for C#/.Net
7. Social Media Network Analysis Workshop
8. University of Miami College of Engineering to develop new methods for data analysis
9. Biosensor chip enables high-sensitivity protein analysis for disease diagnosis
10. MetaGeek Announces Chanalyzer Pro Spectrum Analysis Software for Wi- Spy, Adds Device Classification, Device Finder and Automated Reports
11. Voice Analysis May Allow Early Detection of Parkinsons
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Analysis Confirms Avandia May Harm the Heart
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s spiritual journey ... author, Julianne Hale, a consultant for the Intelligence Community. For more than ... the Near East region. Julianne has written hundreds of reports for the ...
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis Health ... for t4 Leadership Development & Consulting. He has spent his career focusing on ... leadership development, servant leadership, data driven process improvement, and supportive technology. These key ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Call Of ... Duty” is the creation of published author, C.S. Lizarde. Growing up on the ... untimely trials. When Carlos began to apply the Biblical keys to his life, ...
(Date:8/21/2017)... ... , ... PracticeMatch, a company that provides online resources , job ... practitioners like nurse practitioners and physician assistants , will conduct its ... year. The online career fairs will allow job seekers to connect with healthcare employers ...
(Date:8/21/2017)... ... August 22, 2017 , ... ... Stevens as a 2017-2018 inductee into its VIP Woman of the Year ... is the nation’s leading networking organization exclusively for professional women, boasting more than ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/4/2017)... 4, 2017 The search for test results ... physician/patient consult has long been the goal of healthcare ... focus of the largest meeting of lab professionals and ... market research firm Kalorama Information.  The firm said scores ... or related supplies and software were at the American ...
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
Breaking Medicine Technology: